Plasma protein therapies include plasma-derived therapies and recombinant blood clotting factors. These unique, non-interchangeable biological products for which no generics or substitutions exist are used to treat bleeding disorders, primary immunodeficiency diseases, alpha-1 antitrypsin deficiency, and certain rare neurological disordersAbout PPTAPPTA represents the private sector manufacturers of plasma-derived and recombinant analog therapies, collectively known as plasma protein therapies and the collectors of source plasma used for fractionation. PPTA member companies produce approximately 80% of the therapies in the U.S. and 60% of those manufactured in Europe. PPTA works globally to advocate for access to and affordability of therapies; engage in constructive dialogue with regulatory authorities and collaborate with patient organizations. PPTA also administers standards and programs that help ensure the quality and safety of plasma, manufacturing, donors and patients.
PPTA Applauds Preserving Access To Orphan Drugs Acts
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts